Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETRA-pilot testosterone dose-finding after vaginoplasty in transgender women
NL-OMON51335Phase 2Active, not recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of AndroForte in Hypogonadism, sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoints: Serum total testosterone concentration by dose level, Achievement of target testosterone range and 1 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
AndroForte
03
Conditions
Hypogonadism
Beyond the preview
Go deeper on NL-OMON51335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51335.